CV safety is currently under investigation for tirzepatide in patients with obesity without diabetes (NCT05556512) and for cagrilintide/semaglutide with overweight and obesity with and without diabetes (NCT05669755)
They aim to understand how GLP-1 drugs, like Ozempic, affect mental health
Media and Third-Party Validation Major issues This is the weakest point in Willows entire review
As of February 23, 2026, Eli Lilly and Company has a promotion for the Zepbound Self Pay Journey Program, which lowers rates to $449 for each 1-month supply of the 7.5 mg, 10 mg, 12.5 mg, and 15 mg Zepbound single-dose vial or Zepbound KwikPen for single-patient-use
It's the strongest precedent for dose-splitting in peptide therapy
"Thanks to Oana, my menstrual cycles are more regular, and my skin has improved significantly